BG108325A - Нови 4-анилинохинолин-3-карбоксамиди - Google Patents
Нови 4-анилинохинолин-3-карбоксамиди Download PDFInfo
- Publication number
- BG108325A BG108325A BG108325A BG10832503A BG108325A BG 108325 A BG108325 A BG 108325A BG 108325 A BG108325 A BG 108325A BG 10832503 A BG10832503 A BG 10832503A BG 108325 A BG108325 A BG 108325A
- Authority
- BG
- Bulgaria
- Prior art keywords
- methoxy
- quinol
- amino
- quinolinecarboxamide
- dimethoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0101675A SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Novel composition |
Publications (1)
Publication Number | Publication Date |
---|---|
BG108325A true BG108325A (bg) | 2004-11-30 |
Family
ID=20284085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG108325A BG108325A (bg) | 2001-05-11 | 2003-11-07 | Нови 4-анилинохинолин-3-карбоксамиди |
Country Status (25)
Country | Link |
---|---|
US (2) | US7037925B2 (no) |
EP (1) | EP1387830A1 (no) |
JP (1) | JP2004533452A (no) |
KR (1) | KR20040007547A (no) |
CN (1) | CN1286815C (no) |
AR (1) | AR037489A1 (no) |
BG (1) | BG108325A (no) |
BR (1) | BR0209431A (no) |
CA (1) | CA2446717A1 (no) |
CZ (1) | CZ20033034A3 (no) |
EE (1) | EE200300544A (no) |
HU (1) | HUP0401339A2 (no) |
IL (1) | IL158517A0 (no) |
IS (1) | IS7016A (no) |
MX (1) | MXPA03010207A (no) |
MY (1) | MY134136A (no) |
NO (1) | NO20034992D0 (no) |
NZ (1) | NZ529302A (no) |
PL (1) | PL366766A1 (no) |
RU (1) | RU2281940C2 (no) |
SE (1) | SE0101675D0 (no) |
SK (1) | SK13712003A3 (no) |
UA (1) | UA76142C2 (no) |
WO (1) | WO2002092571A1 (no) |
ZA (1) | ZA200308350B (no) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2491191C (en) | 2002-07-15 | 2014-02-04 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
TWI328009B (en) * | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
EP1650192A4 (en) | 2003-07-24 | 2007-03-21 | Astellas Pharma Inc | QUINOLONE DERIVATIVE OR SALT THEREOF |
ATE517091T1 (de) | 2003-09-26 | 2011-08-15 | Exelixis Inc | C-met-modulatoren und verwendungsverfahren |
GB0322722D0 (en) * | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
US7626030B2 (en) | 2004-01-23 | 2009-12-01 | Amgen Inc. | Compounds and methods of use |
SE0400284D0 (sv) * | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Novel compounds |
JP2007536310A (ja) * | 2004-05-03 | 2007-12-13 | ノバルティス アクチエンゲゼルシャフト | S1p受容体アゴニストおよびjak3キナーゼ阻害剤を含む、組合せ剤 |
CA2581516C (en) | 2004-10-12 | 2013-06-11 | Astrazeneca Ab | Quinazoline derivatives |
BRPI0518222A (pt) * | 2004-10-19 | 2008-11-04 | Hoffmann La Roche | composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos |
DK1945631T3 (da) | 2005-10-28 | 2012-10-22 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer |
WO2007099323A2 (en) * | 2006-03-02 | 2007-09-07 | Astrazeneca Ab | Quinoline derivatives |
UY30183A1 (es) * | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
AU2007225088B2 (en) * | 2006-03-13 | 2012-09-13 | Kyorin Pharmaceutical Co., Ltd | Aminoquinolones as GSK-3 inhibitors |
UY30282A1 (es) * | 2006-04-14 | 2007-11-30 | Astrazeneca Ab | Compuestos quimicos |
WO2007139496A1 (en) * | 2006-05-30 | 2007-12-06 | Clanotech Ab | Quinoline derivatives acting as tyrosine kinase inhibitors |
TW200829555A (en) * | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
CL2008000191A1 (es) * | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
CA2699151A1 (en) | 2007-09-11 | 2009-03-19 | Activx Biosciences, Inc. | Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors |
MX2010002662A (es) | 2007-09-12 | 2010-04-09 | Activx Biosciences Inc | Aminoquinolonas espirociclicas como inhibidores de gsk-3. |
ES2546502T3 (es) | 2008-04-16 | 2015-09-24 | Portola Pharmaceuticals, Inc. | 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
JP2011520804A (ja) * | 2008-05-07 | 2011-07-21 | アストラゼネカ アクチボラグ | 化合物 |
WO2010058846A1 (ja) * | 2008-11-21 | 2010-05-27 | アステラス製薬株式会社 | 4,6-ジアミノニコチンアミド化合物 |
TW202241853A (zh) | 2009-01-16 | 2022-11-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
EP2406266B1 (en) | 2009-03-11 | 2013-12-25 | Kyorin Pharmaceutical Co., Ltd. | 7-cycloalkylaminoquinolones as gsk-3 inhibitors |
US8367689B2 (en) | 2009-05-06 | 2013-02-05 | Portola Pharmaceuticals, Inc. | Inhibitors of JAK |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
CN103153063B (zh) | 2010-07-30 | 2016-02-17 | 肿瘤疗法科学股份有限公司 | 喹啉衍生物及含有其的melk抑制剂 |
UY33549A (es) * | 2010-08-10 | 2012-01-31 | Glaxo Group Ltd | Quinolil aminas como agentes inhibidores de las quinasas |
EP2975027A1 (en) | 2010-11-01 | 2016-01-20 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
AU2012225735B2 (en) | 2011-03-04 | 2016-03-10 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
EA026939B1 (ru) | 2011-11-23 | 2017-06-30 | Портола Фармасьютикалз, Инк. | Пиразиновые ингибиторы киназы |
TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基-喹啉類 |
JP6669499B2 (ja) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物 |
JP2016510000A (ja) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物およびその使用 |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
KR20150118152A (ko) | 2013-02-21 | 2015-10-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 키나제 억제제로서의 퀴나졸린 |
KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10227355B2 (en) | 2015-02-03 | 2019-03-12 | Council Of Scientific And Industrial Research | Quinoline derivatives and preparation thereof |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2017324251A1 (en) | 2016-09-08 | 2019-03-21 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10723701B2 (en) | 2016-10-18 | 2020-07-28 | Beijing Konruns Pharmaceutical Co., Ltd. | Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3037925A (en) * | 1958-04-09 | 1962-06-05 | Smith Corp A O | Cathodically protected structure and method of making same |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
HUP0103386A3 (en) * | 1998-08-21 | 2002-07-29 | Parker Hughes Inst St Paul | Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect |
-
2001
- 2001-05-11 SE SE0101675A patent/SE0101675D0/xx unknown
-
2002
- 2002-05-03 AR ARP020101633A patent/AR037489A1/es not_active Application Discontinuation
- 2002-05-06 JP JP2002589457A patent/JP2004533452A/ja active Pending
- 2002-05-06 HU HU0401339A patent/HUP0401339A2/hu unknown
- 2002-05-06 IL IL15851702A patent/IL158517A0/xx unknown
- 2002-05-06 SK SK13712003A patent/SK13712003A3/sk unknown
- 2002-05-06 CN CNB02809722XA patent/CN1286815C/zh not_active Expired - Fee Related
- 2002-05-06 CZ CZ20033034A patent/CZ20033034A3/cs unknown
- 2002-05-06 RU RU2003131679/04A patent/RU2281940C2/ru not_active IP Right Cessation
- 2002-05-06 EP EP02733657A patent/EP1387830A1/en not_active Withdrawn
- 2002-05-06 MX MXPA03010207A patent/MXPA03010207A/es unknown
- 2002-05-06 NZ NZ529302A patent/NZ529302A/en unknown
- 2002-05-06 PL PL02366766A patent/PL366766A1/xx unknown
- 2002-05-06 CA CA002446717A patent/CA2446717A1/en not_active Abandoned
- 2002-05-06 BR BR0209431-2A patent/BR0209431A/pt not_active IP Right Cessation
- 2002-05-06 US US10/477,254 patent/US7037925B2/en not_active Expired - Fee Related
- 2002-05-06 KR KR10-2003-7014579A patent/KR20040007547A/ko not_active Application Discontinuation
- 2002-05-06 WO PCT/SE2002/000875 patent/WO2002092571A1/en active IP Right Grant
- 2002-05-06 EE EEP200300544A patent/EE200300544A/xx unknown
- 2002-05-09 MY MYPI20021680A patent/MY134136A/en unknown
- 2002-06-05 UA UA2003109525A patent/UA76142C2/uk unknown
-
2003
- 2003-10-27 ZA ZA200308350A patent/ZA200308350B/en unknown
- 2003-11-05 IS IS7016A patent/IS7016A/is unknown
- 2003-11-07 BG BG108325A patent/BG108325A/bg unknown
- 2003-11-10 NO NO20034992A patent/NO20034992D0/no not_active Application Discontinuation
-
2006
- 2006-03-06 US US11/368,914 patent/US20060173034A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MY134136A (en) | 2007-11-30 |
BR0209431A (pt) | 2004-08-03 |
KR20040007547A (ko) | 2004-01-24 |
RU2281940C2 (ru) | 2006-08-20 |
HUP0401339A2 (hu) | 2004-12-28 |
NZ529302A (en) | 2004-08-27 |
SK13712003A3 (en) | 2004-10-05 |
CN1507434A (zh) | 2004-06-23 |
PL366766A1 (en) | 2005-02-07 |
EP1387830A1 (en) | 2004-02-11 |
EE200300544A (et) | 2004-02-16 |
RU2003131679A (ru) | 2005-05-10 |
ZA200308350B (en) | 2005-01-27 |
AR037489A1 (es) | 2004-11-17 |
MXPA03010207A (es) | 2004-03-10 |
CN1286815C (zh) | 2006-11-29 |
NO20034992D0 (no) | 2003-11-10 |
US7037925B2 (en) | 2006-05-02 |
CZ20033034A3 (en) | 2004-06-16 |
US20040248923A1 (en) | 2004-12-09 |
IS7016A (is) | 2003-11-05 |
WO2002092571A1 (en) | 2002-11-21 |
US20060173034A1 (en) | 2006-08-03 |
HU0401339D0 (en) | 2004-08-30 |
SE0101675D0 (sv) | 2001-05-11 |
JP2004533452A (ja) | 2004-11-04 |
IL158517A0 (en) | 2004-05-12 |
CA2446717A1 (en) | 2002-11-21 |
UA76142C2 (en) | 2006-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG108325A (bg) | Нови 4-анилинохинолин-3-карбоксамиди | |
US20080153799A1 (en) | Novel Quinoline-Carbaxamides as Jak3 Kinase Modulators | |
ES2457396T3 (es) | 3-Cianoquinolinas sustituidas como inhibidores de las proteínas tirosina quinasas | |
EP1178965B1 (en) | Quinoline derivatives as inhibitors of mek enzymes | |
US20040029898A1 (en) | Substituted quinolines as antitumor agents | |
EP2799437B1 (en) | Quinoline and cinnoline derivatives and use thereof | |
WO2003000660A1 (en) | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same | |
WO2000068201A1 (en) | Quinoline derivatives as inhibitors of mek enzymes | |
JP2007008816A (ja) | 新規イソキノリン誘導体 | |
AU2003215678A1 (en) | Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents | |
WO2012016082A1 (en) | Quinoline derivatives and melk inhibitors containing the same | |
WO2004113303A1 (en) | INDAZOLE/PYRZOLO[4,3-c]PYRIDIN DERIVATIVES AS JNK INHIBITORS, COMPOSITIONS AND METHODS RELATED THERETO AS WELL AS INTERMEDIATE THEREOF | |
EA002124B1 (ru) | Производные хинолина | |
JP2004517059A (ja) | 抗腫瘍剤用の4−置換キノリン類 | |
WO2006077851A1 (ja) | キノロン誘導体又はその塩 | |
CZ20013660A3 (cs) | Substituované 3-kyano-(1,7),(1,5) a (1,8)-naftyridinové inhibitory tyrosinových kináz | |
CA2505910C (en) | Imidazoquinoline derivatives as adenosine a3 receptor ligands | |
JP2007500689A (ja) | アミノキノリン誘導体およびアデノシンa3リガンドとしてのそれらの使用 | |
KR102526281B1 (ko) | 옥사지노-퀴나졸린 및 옥사지노-퀴놀린형 화합물, 이의 제조방법 및 용도 | |
JP4530663B2 (ja) | イミダゾキノリン誘導体 | |
US7501449B2 (en) | 2H -or 3H-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof | |
AU2002306038A1 (en) | Novel 4-anilinoquinoline-3-carboxamides | |
CN114728963B (zh) | 新型三唑吡啶衍生物和包括其的药物组合物 | |
JPH0633255B2 (ja) | テトラヒドロキノリン誘導体 |